LGND News and Press, Ligand Pharmaceuticals Incorporated From 02/22/23

Ligand Pharmaceuticals press release ( NASDAQ: LGND ): Q4 Non-GAAP EPS of $1.36 beats by $0.24 . Revenue of $50.38M (-10.7% Y/Y) beats by $10.75M . Now expect 2023 royalties of $74 million to $78 million (previously $72 million to $76 million), sales of Captisol of $21...

2023 Financial Guidance Raised Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2022, and provided an operating forecast and business upda...

First single molecule Dual Endothelin Angiotensin Receptor Antagonist (DEARA) approved for use in patients with IgA nephropathy (IgAN) Interim results from the ongoing Phase 3 PROTECT head-to-head trial demonstrated a rapid, sustained and clinically meaningful reduction in proteinuria vs. act...

Sermonix Pharmaceuticals and Quantum Leap Healthcare Announce New Study Arm to Evaluate Lasofoxifene in Ongoing I-SPY 2 Clinical Trial PR Newswire COLUMBUS, Ohio, and SAN FRANCISCO , Feb. 16, 2023 /PRNewswire/ -- Sermonix Pharmaceuticals Inc. and Quantum Lea...

H.C. Wainwright has initiated OmniAb ( NASDAQ: OABI ) with a buy rating saying that the antibody discovery technology company is set to benefit from collaborations and partnerships with other companies. The firm has an $11 price target (~184% upside based on Friday's close). Analy...

Summary Bumbershoot Holdings uses a fundamental investment strategy as a “quality over quantity” approach to identifying and evaluating great businesses. It primarily invests in small- and mid- capitalization public companies. Bumbershoot Holdings registered a gain of +1.2...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report fourth quarter 2022 financial results after the close of the U.S. financial markets on Wednesday, February 22, 2023 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Speakers on the call will include...

Novan ( NASDAQ: NOVN ) has submitted a New Drug Application to the US FDA for berdazimer gel for the topical treatment of viral skin infection molluscum contagiosum. The submission is the first for the company. The application is supported by data from a phase 3 trial that showe...

Potential FDA approval anticipated in the first quarter of 2024, assuming FDA filing acceptance and standard review timelines Molluscum contagiosum is a viral skin infection that affects approximately 6 million people, mostly children Berdazimer gel, 10.3% has the potential to be the firs...

Summary Ligand's spinoff of OmniAb has rightsized Ligand as it faces revenue challenges. Ligand's management changes should be productive for it. Several key catalysts are poised to enhance its portfolio to address expected revenue reductions. My inaugural Ligand (LGND) ...